SHAREHOLDER ALERT: Monteverde & Associates PC Reveals a Probe of Pandion Therapeutics, Inc. - PAND

NEW YORK, Feb. 27: Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a countrywide securities organisation rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report with its headquarters at the Empire State Building in New York City, is probing Pandion Therapeutics, Inc. ("PAND" or the "Company") (PAND) connecting to its planned procurement by Merck. Under the terms of the agreement, PAND shareholders will obtain $60.00 in cash per share. The investigation focuses on whether Pandion Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued. We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.